Comparing effectiveness of antiviral (acyclovir) as oral medication, cream and local injection form for genital (Private area) and anal warts.

Comparative efficacy of oral, topical and intralesional acyclovir in anogenital warts - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/08/093570

Enrollment

Registered

2025-08-25

Start date

Unknown

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A630- Anogenital (venereal) warts

Interventions

Intervention1: Oral Tab Acyclovir 400mg: Patients will be given oral acyclovir tablets in the dose of 400mg thrice a day for 4 weeks. Intervention2: Topical 5% acyclovir cream: Patients will be given

Eligibility

Inclusion criteria

Inclusion criteria: All consecutive patients having lesions of anogenital warts.

Exclusion criteria

Exclusion criteria: 1.Pregnant or females planning for pregnancy or lactating mothers. 2.Immunocompromised individuals including HIV-AIDS. 3.Patients with known hypersensitivity to acyclovir or its components or any contraindications to acyclovir e.g. renal failure. 4.Patients having any significant systemic illness. 5.Patients having taken any other treatments for anogenital warts in the last 4 weeks.

Design outcomes

Primary

Measure	Time frame
To evaluate the resolution of lesionsTimepoint: Every week for 4 weeks	—

Secondary

Measure	Time frame
To evaluate the resolution/recurrence of lesionsTimepoint: at 8 weeks, after 4 weeks of stoppage of therapy;To assess the adverse effects of oral, topical and intralesional formulations of acyclovirTimepoint: 8 weeks total study duration	—

Countries

India

Contacts

Public ContactDr Rahul Dogra

Government Medical College and Hospital Chandigarh

thamigp@yahoo.com9646121544

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026